In its fourth-quarter investor presentation, Endo International (ENDP) guided for its fiscal 2019 adjusted operating expenses as a percentage of revenue being 24.5%–25.0%.
In its fourth-quarter investor presentation, Endo International (ENDP) guided for adjusted diluted EPS and adjusted EBITDA of $2.00–$2.25 and $1.24 billion–$1.34 billion, respectively, in fiscal 2019.
In its fourth-quarter investor presentation, Endo International (ENDP) guided for fiscal 2019 revenue of $2.76 billion–$2.96 billion, representing a low single-digit percentage YoY (year-over-year) decline.
Most analysts covering Endo International (ENDP) and Mallinckrodt (MNK) recommend “hold.” On March 5, Endo closed at $8.72, and Mallinckrodt closed at $22.39.
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.
Mylan (MYL) reported revenues of $2.99 billion in 3Q17, a 2.3% decline from revenues of $3.06 billion in 3Q16. This total includes net product sales of $2.96 billion and other revenues of $30.8 million in 3Q17.
Mallinckrodt Pharmaceuticals, which produces specialty pharmaceutical products such as generic drugs and imaging agents, surged to a ten-day high on May 26.
After closing last week almost unchanged, the health care sector started the week on a weaker note. On Tuesday, the S&P 500 Health Care sector fell 0.45%.
Merck’s profitability improved via a 5% rise in revenue in 3Q16. Its adjusted net income rose to ~$2.3 billion in 3Q16, compared to ~$1.8 billion in 3Q15.
Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.
On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.
Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.
Revenue projections for Mallinckrodt According to Reuters, Mallinckrodt’s (MNK) mean revenue for fiscal 2016 should amount to $3.4 billion. Analysts expect an average YoY (year-over-year) growth of 1.5% in 2016. The anchors behind MNK’s growth are Ofirmev, Acthar, and INOmax, along with the recently acquired Stratatech. As Acthar caters to 3% of the total eligible […]
Share price estimates for Mallinckrodt Mallinckrodt (MNK) is a specialty biopharmaceutical company. According to Reuters, of 14 brokerage firms surveyed on November 26, 2016, 64% recommended Mallinckrodt as a “buy.” Of these “buy” ratings, 29% were “strong buy,” while 36% were “buy.” Around 36% of the firms issued a “hold” rating on the company. Mean […]
Acthar Of Mallinckrodt’s (MNK) $3.4 billion total revenue in 2015, Acthar’s contribution was $1 billion. Therefore, Mallinckrodt is highly dependent on Acthar. While the product is approved for 19 indications, most of the growth flows from rheumatology and pulmonology. During 2Q16 and 3Q16, the product grew annually by 11%. In rheumatology, the drug caters to […]
Mallinckrodt (MNK) has recently been making news due to its business model being questioned. A Citron Research report focused on the sustainability of Acthar’s higher level of exposure to government-oriented franchise.
Trump’s win and Valeant Pharmaceuticals Valeant Pharmaceuticals (VRX) has been quite volatile over the past five days. On November 8, election day, Valeant announced its earnings. With a lower growth outlook for 2016 and underperformance expected to continue in 2017, Valeant fell 21%. With the election results, Valeant jumped to $16.09 from $14.98 the day […]
The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.
David Einhorn discussed some pharmaceuticals companies at the 2016 annual Great Investors’ Best Ideas (or GIBI) investment symposium in Dallas on Tuesday, October 18, 2016.
Valeant will report all assets with falling revenues—and all assets that need to be optimized for earning high cash returns—in its Cash Generating segment.
To boost profitability and share prices, Valeant plans to focus on five strategic imperatives to help it pose stronger competition to ENDP, MNK, and GILD.
According to a Bloomberg consensus of 12 brokerage firms recorded on September 19, 2016, 83.3% of the firms rated Horizon a “buy,” while 16.7% rated it a “hold.”
Share price estimates for Valeant Valeant Pharmaceuticals (VRX) operates in the specialty pharmaceutical industry. With controversies associated with its huge debt, price gouging, and the Philidor controversy, the stock has fallen ~73% YTD (year-to-date). According to a Bloomberg survey of 22 brokerage firms recorded on September 14, 2016, 31.8% of the firms rated Valeant as […]
Is Valeant decreasing prices for its controversial drugs? Valeant Pharmaceuticals’ (VRX) drugs Isuprel and Nitropress were scrutinized for price gouging. For details on the pricing controversy associated with these two drugs, you can read The Facts behind the Valeant Drug Pricing Controversy. Following a discussion with the Patient Access and Pricing Committee, Valeant announced an enhanced rebate […]
On August 16, Horizon Pharma was trading at a forward price-to-sales ratio of 3x—a premium compared to its specialty pharma peers Mallinckrodt and Endo.
With its inorganic growth–focused business model, Valeant Pharmaceuticals (VRX) has accumulated huge long-term debt amounting to ~$31.1 billion, as of June 30, 2016.
Mallinckrodt reported its fiscal 3Q16 earnings on August 2, 2016. Analysts expected revenue for the period to be ~$921.9 million, and MNK surprised them.
During 4Q15 and 1Q16, Valeant Pharmaceuticals’ (VRX) net margin turned negative. That followed its struggling high-margin dermatology products and the foreign exchange impact.
Valeant Pharmaceuticals International (VRX) is expected to report its 2Q16 earnings on August 9, 2016. About 27.3% of analysts have rated Valeant a “buy.”
Horizon operates through three segments: Primary Care, Orphan Drugs, and Rheumatology. It proposes to become an orphan disease drug company by fiscal 2020.
On June 29, 2016, Horizon Pharma was trading at a forward PS multiple of 2.10x. This seemed to be at a premium over Mallinckrodt and Endo International.
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
On June 28, 2016, Neurocrine Biosciences was trading at a forward PS multiple of ~25.7x. Since January 1, it’s been trading at PS multiples of 22.2x–40.2x.
Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage.
Valeant’s (VRX) controversies started with Philidor, a specialty pharmacy company that was accused of altering doctor’s prescriptions so it could sell more of Valeant’s costly drugs.
Much of Valeant’s growth was coming from price increases rather than volume gains, and that wasn’t sustainable. The company’s steep price increases came under regulator scrutiny.
According to a Bloomberg survey of 22 analysts on June 8, 2016, 31.8% of them rated Valeant a “buy,” while 45.5% rated it a “hold.” About 22.7% gave the stock a “sell” rating.
The consensus 12-month target price for Mallinckrodt is $90.7. This translates to a ~39.8% return compared to its closing price of $64.8 on May 3, 2016.
In fiscal 2Q16, Mallinckrodt’s R&D expenses stood at $58.6 million, ~6.4% of net sales. After restructuring, it moved some medical costs from R&D to SG&A.
